[ON DEMAND] Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized, progressive, and life-threatening condition often hidden behind common arrhythmias such as atrial fibrillation. As diagnostic tools advance, electrophysiologists are uniquely positioned to play a critical role in the early detection and management of this underdiagnosed disease.
Join the Heart Rhythm Society and BridgeBio for a one-hour interactive webinar exploring the clinical features, diagnostic challenges, and electrophysiologic considerations of ATTR-CM. Expert faculty will share insights into disease pathology, early warning signs, and strategies for timely diagnosis and multidisciplinary management—helping clinicians improve outcomes for patients with structural heart disease and arrhythmias.
Learning Objectives
- Increase awareness of ATTR-CM.
- Improve diagnostic confidence and competence.
- Enhance clinical decision-making.
- Apply case-based learning.
Participants
Moderator
Tina Baykaner, MD, MPH | Stanford University
Panelists
Kevin Michael Alexander, MD | Stanford University
Mazen Hanna, MD | Cleveland Clinic
Wael Jaber, MD | Cleveland Clinic
Roy M. John, MD, PhD, FRCP | Stanford University
Konstantinos Siontis, MD | Mayo Clinic